Format

Send to

Choose Destination
Clin Infect Dis. 2017 Mar 15;64(suppl_1):S3-S7. doi: 10.1093/cid/ciw824.

The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress.

Author information

1
University of California, San Francisco, San Francisco General Hospital.
2
Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina.
3
Center for Biostatistics in AIDS Research and Department of Biostatistics, Harvard University, Boston, Massachusetts.
4
Public Health Research Institute Tuberculosis Center, New Jersey Medical School-Rutgers University, Newark; and.
5
Division of Infectious Diseases, Department of Medicine, Duke University Medical Center, Durham, North Carolina.

Abstract

The Antibacterial Resistance Leadership Group (ARLG), with funding from the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, was created in June 2013. Its mission is to develop, prioritize, and implement a clinical research agenda that addresses the public health threat of antibacterial resistance. This article reports on the progress that the ARLG has made to date in fulfilling its mission. Since inception, the ARLG has received and reviewed >70 study proposals, initiated >30 studies, executed >300 agreements, included data from >7000 subjects, published >45 manuscripts, and provided opportunities for 26 mentees. Despite this substantial progress, there remains significant work to be accomplished. This article also describes the considerable challenges that lie ahead.

KEYWORDS:

antibacterial resistance; clinical trials.; diagnostics; network; stewardship

PMID:
28350896
PMCID:
PMC5850447
DOI:
10.1093/cid/ciw824
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center